Literature DB >> 7053758

Mode of action of the IgG inhibitor of erythropoiesis in transient erythroblastopenia of children.

E N Dessypris, S B Krantz, J S Roloff, J N Lukens.   

Abstract

Twelve cases of transient erythroblastopenia of childhood (TEC) have been studied to evaluate their marrow cell erythropoiesis in vitro and the effect on it of their serum or IgG. The number of colony-forming units-erythroid (CFU-E) and burst-forming units-erythroid (BFU-E) in the bone marrow of nine cases was extremely variable and did not allow any conclusion regarding the pathogenesis of this anemia. An IgG inhibitor of growth of erythroid colonies or bursts was detected in 8/12 cases. This IgG inhibitor had no effect on the growth of granulocyte-macrophage colonies. Further studies on its mode of action indicated that the IgG did not have antierythropoietin antibody properties and did not affect the mature erythroblasts, as shown by a lack of inhibition of their responses to erythropoietin and by the lack of a cytotoxic effect on 59Fe-labeled erythroblasts. In four cases, preincubation studies demonstrated a direct effect of the IgG on the CFU-E, which was complement-mediated in three cases and complement-independent in one case. In two other cases, the IgG suppressed the growth of normal BFU-E only without affecting the growth of CFU-E. The IgG inhibitor was no longer present after the erythroblastopenia had remitted. These studies demonstrate that in the majority of cases of TEC, an IgG suppressor of erythropoiesis in vitro is present. Its mode of action is heterogeneous regarding its requirement for complement. Its target cells are the earlier or later erythroid progenitors, BFU-E or CFU-E, but not the differentiated erythroblasts.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7053758

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis.

Authors:  Jeffrey M Lipton; Steven R Ellis
Journal:  Hematol Oncol Clin North Am       Date:  2009-04       Impact factor: 3.722

2.  Transient erythroblastopenia of childhood with CD10, TdT, and cytoplasmic mu lymphocyte positivity in bone marrow.

Authors:  A B Foot; M N Potter; J E Ropner; T B Wallington; A Oakhill
Journal:  J Clin Pathol       Date:  1990-10       Impact factor: 3.411

3.  Increase of CALLA-positive stimulated lymphoid cells in transient erythroblastopenia of childhood.

Authors:  S Leuschner; S Bödewaldt-Radzun; M Rister
Journal:  Eur J Pediatr       Date:  1990-05       Impact factor: 3.183

4.  Antibody-dependent cellular cytotoxicity to allogeneic but not autologous erythroblasts in vitro.

Authors:  S B Krantz; E N Dessypris
Journal:  J Clin Immunol       Date:  1982-07       Impact factor: 8.317

5.  Monoclonal gammopathy-associated pure red cell aplasia.

Authors:  Neha Korde; Yong Zhang; Kelsey Loeliger; Andrea Poon; Olga Simakova; Adriana Zingone; Rene Costello; Richard Childs; Pierre Noel; Samuel Silver; Mary Kwok; Clifton Mo; Neal Young; Ola Landgren; Elaine Sloand; Irina Maric
Journal:  Br J Haematol       Date:  2016-03-21       Impact factor: 6.998

6.  Transient erythroblastopenia of childhood. A review of 22 cases.

Authors:  G P Gerrits; C G van Oostrom; G A de Vaan; J A Bakkeren
Journal:  Eur J Pediatr       Date:  1984-09       Impact factor: 3.183

7.  Human megakaryocytic progenitor cells.

Authors:  L Kanz; G W Löhr; A A Fauser
Journal:  Klin Wochenschr       Date:  1987-04-01

8.  Variable in vitro erythropoiesis in patients with transient erythroblastopenia of childhood.

Authors:  A K Ritchey; N Dainiak; R Hoffman
Journal:  Yale J Biol Med       Date:  1985 Jan-Feb

9.  Dental considerations in a paediatric patient with Diamond-Blackfan anaemia.

Authors:  Imam Azam; Morankar Rahul; Nitesh Tewari; Kalpana Bansal
Journal:  BMJ Case Rep       Date:  2020-09-14

10.  Rational management approach to pure red cell aplasia.

Authors:  Suresh Kumar Balasubramanian; Meena Sadaps; Swapna Thota; Mai Aly; Bartlomiej P Przychodzen; Cassandra M Hirsch; Valeria Visconte; Tomas Radivoyevitch; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.